Navigation Links
HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College

SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).

The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM.  HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs.  HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."

Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science College, commented, "Our College is dedicated to promoting TCM innovations. We are delighted to collaborate with HUYA and together we will share the commitment towards the global development of novel therapeutics from TCM in areas of unmet medical need."


HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at


Zhejiang Chinese Medical University Life Science College, established in April 2000, is a successor of the Institute of Molecular Medicine. The college has six research departments: Biochemistry, Genetics and Molecular Biology, Cell Biology, Microbiology and Immunology, General Biology, and Clinical Laboratory Science. With well-defined missions, elite faculty, and outstanding educational subjects, Zhejiang Chinese Medical University Life Science College is now a leading institute for TCM in China. It has received various awards, developed two new drugs (one successfully marketed), undertaken a significant number of projects, and published numerous papers. For more information, please visit


Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International

Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
2. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
3. BD Biosciences Announces Winners of Research Grant Program
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Numira Biosciences Names New Board Member
6. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
11. Roka Bioscience Participates in the International Association for Food Protection Conference
Post Your Comments:
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique shows ... the preliminary results of a study being presented today at ... North America (RSNA). --> ... for decades by interventional radiologists as a way to stop ... procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... additional independent director, and the Company welcomes Neil ... in a recent anonymous internet report on NW Bio.  ... Linda Powers stated, "We agree with ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):